The Registry of Toxic Effects of Chemical Substances

2 - Naphthylamine

RTECS #: QM2100000

CAS #: 91-59-8

UPDATE: May 2005 MW: 143.20 MF: C10H9N


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. TUMORIGENIC DATA:
  4. ACUTE TOXICITY DATA:
  5. REVIEWS:
  6. STANDARDS AND REGULATIONS:
  7. NIOSH DOCUMENTATION AND SURVEILLANCE:
  8. STATUS IN FEDERAL AGENCIES:
  9. REFERENCES:

SYNONYMS:

  1. 2 - AN
  2. 2 - Aminonaftalen (Czech)
  3. 2 - Aminonaphthalene
  4. 2 - Naftylamin (Czech)
  5. 2 - Naftylamine (Dutch)
  6. 2 - Naphthalamine
  7. 2 - Naphthalenamine
  8. 2 - Naphthylamin (German)
  9. 2 - Naphthylamine mustard
  10. 6 - Naphthylamine
  11. C.I. 37270
  1. Fast Scarlet Base B
  2. RCRA waste number U168
  3. USAF CB - 22
  4. beta - Naftalamin (Czech)
  5. beta - Naftilamina (Italian)
  6. beta - Naftylamin (Czech)
  7. beta - Naftyloamina (Polish)
  8. beta - Naphthylamin (German)
  9. beta - Naphthylamine
  10. beta - Naphthylamine (ACGIH:OSHA)


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
body fluid assay rat
Salmonella typhimurium 		250 µmol/kg TXCYAC 16,113,1980
cytogenetic analysis hamster ovary 3,330 µg/L PMRSDJ 1,551,1981
cytogenetic analysis multiple
non-mammalian species 		2,500 µg/L MUREAV 319,223,1993
cytogenetic analysis intraperitoneal
rat 		6 mg/kg/72 hour NULSAK 23,36,1980
cytogenetic analysis rat liver 50 mg/L PMRSDJ 1,570,1981
DNA adduct oral
dog 		60 µmol/kg EVHPAZ 49,125,1983
DNA adduct oral
dog 		8 mg/kg CRNGDP 2,467,1981
DNA adduct Escherichia coli 30 µmol/L MUREAV 89,95,1981
DNA adduct mouse Ascites tumor 30 µmol/L MUREAV 89,95,1981
DNA damage Bacillus subtilis 2 mg/disc PMRSDJ 1,175,1981
DNA damage human fibroblast 50 µmol/L MUREAV 127,107,1984
DNA damage human other cell types 0.5 mmol/L/20 hour TXCYAC 179,115,2002
DNA damage mammal (species unspecified) lymphocyte 1 mmol/L MUREAV 368,235,1996
DNA damage oral
mouse 		400 mg/kg MUREAV 440,1,1999
DNA damage other microorganisms 1 mmol/L MUREAV 368,235,1996
DNA damage intraperitoneal
rat 		1,390 µmol/kg CRNGDP 2,1317,1981
DNA damage rat liver 300 µmol/L MUREAV 113,357,1983
DNA damage rat other cell types 0.25 mmol/L/20 hour TXCYAC 179,115,2002
DNA inhibition human HeLa cell 200 µmol/L MUREAV 92,427,1982
DNA inhibition human HeLa cell 20 mmol/L MUREAV 93,447,1982
DNA inhibition intraperitoneal
mouse 		20 gm/kg ARGEAR 51,605,1981
DNA inhibition rat liver 10 µmol/L CNREA8 45,337,1985
DNA repair Bacillus subtilis 5 gm/L MUREAV 42,19,1977
DNA repair Escherichia coli 25 mg/L JJIND8 62,873,1979
DNA repair Saccharomyes cerevisiae 50 mg/L PMRSDJ 1,502,1981
unscheduled DNA synthesis hamster liver 50 µmol/L MUREAV 136,255,1984
unscheduled DNA synthesis human fibroblast 800 µg/L TXCYAC 21,151,1981
unscheduled DNA synthesis rat liver 10 µmol/L ENMUDM 3,11,1981
host-mediated assay mouse
Escherichia coli 		200 mg/kg MUREAV 272,161,1992
mutation in microorganisms Bacillus subtilis 5 gm/L (+enzymatic activation step) MUREAV 42,19,1977
mutation in microorganisms Escherichia coli 1 µg/plate (+enzymatic activation step) PMRSDJ 1,387,1981
mutation in microorganisms mouse lymphocyte 4,720 µg/L (+enzymatic activation step) EMMUEG 12(Suppl 13),37,1988
mutation in microorganisms Neurospora crassa 200 µmol/L (-enzymatic activation step) CNREA8 32,1890,1972
mutation in microorganisms Salmonella typhimurium 2,500 ng/plate (+enzymatic activation step) PMRSDJ 1,261,1981
mutation in microorganisms Salmonella typhimurium 2 µg/plate (-enzymatic activation step) BECTA6 17,739,1977
mutation in microorganisms Salmonella typhimurium 20 µg/plate/20 minute (+enzymatic activation step) MUREAV 498,19,2001
mutation in microorganisms Salmonella typhimurium 1 nmol/plate/20 minute EMMUEG 38,268,2001
mutation in microorganisms Salmonella typhimurium 4 mg/L/72 hour (+enzymatic activation step) MUREAV 558,181,2004
mutation in microorganisms Saccharomyes cerevisiae 698 µmol/L (-enzymatic activation step) MGGEAE 174,39,1979
mutation in microorganisms Saccharomyes cerevisiae 89 mg/L (+enzymatic activation step) PMRSDJ 1,414,1981
micronucleus test intraperitoneal
mouse 		100 mg/kg PMRSDJ 1,698,1981
micronucleus test oral
mouse 		300 mg/kg/3 day- continuous MUREAV 234,161,1990
micronucleus test multiple
non-mammalian species 		2,500 µg/L MUREAV 283,157,1992
gene conversion and mitotic recombination Saccharomyes cerevisiae 50 ppm PMRSDJ 1,481,1981
mutation in mammalian somatic cells hamster ovary 50 mg/L MUREAV 94,449,1982
mutation in mammalian somatic cells mouse lymphocyte 225 mg/L PMRSDJ 1,580,1981
morphological transform hamster embryo 1,600 µg/L CRNGDP 1,323,1980
morphological transform hamster kidney 25 mg/L PMRSDJ 1,638,1981
morphological transform human other cell types 68 mg/L ITCSAF 17,719,1981
morphological transform mouse embryo 1 mg/L JNCIAM 52,1167,1974
morphological transform mouse mammary gland 1 µg/L CNREA8 39,1784,1979
morphological transform oral
rat 		400 mg/kg CNREA8 40,1157,1980
morphological transform rat embryo 5 mg/L JNCIAM 51,799,1973
other mutation test systems Escherichia coli 7 nmol/tube MUREAV 147,79,1985
phage inhibition capacity Escherichia coli 25 mg/L CNREA8 41,532,1981
sister chromatid exchange hamster ovary 5 mg/L PMRSDJ 1,551,1981
sister chromatid exchange intraperitoneal
mouse 		100 mg/kg MUREAV 108,225,1983
sex chromosome loss and nondisjunction Saccharomyes cerevisiae 50 mg/L PMRSDJ 1,468,1981
specific locus test oral
Drosophila melanogaster 		700 µmol/L CNREA8 30,195,1970
specific locus test intraperitoneal
mouse 		100 mg/kg MUREAV 121,267,1983


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
implant
mouse 		lowest published toxic dose: 100 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		BJCAAI 10,539,1956
intraperitoneal
mouse 		lowest published toxic dose: 1,500 mg/kg/8 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		JJIND8 67,1299,1981
intraperitoneal
rat 		lowest published toxic dose: 1,300 mg/kg/13 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Blood: Lymphoma including Hodgkin's disease

Tumorigenic: Tumors at site of application 		CNREA8 28,535,1968
multiple
dog 		lowest published toxic dose: 3,077 mg/kg/78 week- continuous Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		AJPAA4 13,656,1937
multiple
dog 		toxic dose : 4,379 mg/kg/80 week- continuous Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		JIHTAB 20,46,1938
multiple
dog 		toxic dose : 5,169 mg/kg/91 week- continuous Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		JIHTAB 20,46,1938
oral
dog 		lowest published toxic dose: 18 gm/kg/2 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		JNCIAM 49,193,1972
oral
dog 		toxic dose : 108 mg/kg/4 year Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		LANCAO 2,286,1951
oral
dog 		toxic dose : 94,500 mg/kg/9 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		BJCAAI 44,892,1981
oral
dog 		lowest published toxic dose: 33,600 mg/kg/168 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		VOONC* 37,60,1991
oral
hamster 		lowest published toxic dose: 217 mg/kg/45 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Kidney, Ureter, and Bladder: Bladder tumors 		85DAAC 5,129,1966
oral
hamster 		toxic dose : 365 gm/kg/43 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Kidney, Ureter, and Bladder: Bladder tumors 		IMSUAI 35,564,1966
oral
monkey 		lowest published toxic dose: 17 gm/kg/5 year- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		JNCIAM 42,825,1969
oral
mouse 		lowest published toxic dose: 600 mg/kg/8 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		TXAPA9 82,19,1986
oral
mouse 		toxic dose : 31 gm/kg/2 year Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Liver: Tumors 		LANCAO 2,286,1951
oral
rat 		lowest published toxic dose: 17,100 mg/kg/57 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		BJCAAI 46,646,1982
oral
rat 		toxic dose : 13 gm/kg/1 year- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Tumors

Reproductive: Tumorigenic effects: Testicular tumors 		JNCIAM 41,985,1968
oral
rat 		toxic dose : 16 gm/kg/52 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Kidney, Ureter, and Bladder: Kidney tumors

Skin and Appendages: Tumors 		CNREA8 37,2943,1977
oral
rabbit 		lowest published toxic dose: 40 gm/kg/5 year Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		LANCAO 2,286,1951
oral
rabbit 		toxic dose : 30 gm/kg/5 year Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		LANCAO 2,286,1951
parenteral
mouse 		lowest published toxic dose: 18 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Blood: Lymphoma including Hodgkin's disease 		BECCAN 40,42,1962
subcutaneous
mouse 		lowest published toxic dose: 1,600 mg/kg/40 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application 		VOONAW 15(2),71,1969
subcutaneous
mouse 		toxic dose : 80 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Tumorigenic: Tumors at site of application 		ZEKBAI 58,56,1951
subcutaneous
rat 		lowest published toxic dose: 6 gm/kg/60 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Blood: Lymphoma including Hodgkin's disease

Tumorigenic: Tumors at site of application 		VOONAW 20(8),69,1974
unreported route
dog 		lowest published toxic dose: 40 gm/kg/81 week Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors 		VOONAW 15(2),71,1969


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lethal dose (50 percent kill): 200 mg/kg N/R NTIS** AD277-689
oral
rat 		lethal dose (50 percent kill): 727 mg/kg N/R 85JCAE -,466,1986
unreported route
dog 		lowest published lethal dose: 500 mg/kg Lung, Thorax, or Respiration: Cyanosis

Kidney, Ureter, and Bladder: Hematuria

Blood: Methemoglobinemia- Carboxhemoglobinemia 		XPHBAO 271,176,1941


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value time-weighted average L DTLVS* TLV/BEI,2003
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value Confirmed Human Carcinogen DTLVS* TLV/BEI,2003
International Agency for Research on Cancer (IARC) Cancer Review Human Sufficient Evidence IMEMDT 4,97,1974
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 4,97,1974
International Agency for Research on Cancer (IARC) Cancer Review Group 1 IMSUDL 7,261,1987
TOXICOLOGY REVIEW
KHZHAZ 12(2),85,1976
TOXICOLOGY REVIEW
ADCSAJ 13,271,1970
TOXICOLOGY REVIEW
BLFSBY 24,253,1983


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) see Code of Federal Regulations (CFR) 29,1926.1109 CFRGBR 29,1926.55,1994
Occupational Safety and Health Administration (OSHA) cancer suspect agent CFRGBR 29,1910.1009,1987
Occupational Exposure Limit - AUSTRALIA Carcinogen, JAN1993
Occupational Exposure Limit - AUSTRIA Skin, Carcinogen, JAN1999
Occupational Exposure Limit - BELGIUM Carcinogen, JAN1993
Occupational Exposure Limit - FINLAND Carcinogen, JAN1999
Occupational Exposure Limit - FRANCE VME 0.001 ppm (0.005 mg/m3), continuous1 Carcinogen, JAN1999
Occupational Exposure Limit - FRANCE Carcinogen, JAN1993
Occupational Exposure Limit - GERMANY Skin, Carcinogen, JAN1999
Occupational Exposure Limit - POLAND MAC(time-weighted average) 0 mg/m3, MAC(short term exposure limit) 0 mg/m3, JAN1999
Occupational Exposure Limit - SWEDEN Carcinogen, JAN1999
Occupational Exposure Limit - SWITZERLAND Skin, Carcinogen, JAN1999
Occupational Exposure Limit - UNITED KINGDOM Carcinogen, SEP2000
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN, KOREA American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value;

Confirmed Human Carcinogen
Occupational Exposure Limit IN NEW ZEALAND, SINGAPORE, VIETNAM American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value
Confirmed Human Carcinogen


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO beta-NAPHTHYLAMINE-air Carcinogen use 29 Code of Federal Regulations (CFR) 1910.1009 NIOSH* DHHS #92-100,1992
National Occupational Hazard Survey 1974 National Occupational Hazard Survey 1974: Hazard Code: 50065;
Number of Industries 1;
Total Number of Facilities 10;
Number of Occupations 5;
Total Number of Employees Exposed 420
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: 50065;
Number of Industries 1;
Total Number of Facilities 10;
Number of Occupations 1;
Total Number of Employees Exposed 275;
Total Number of Female Employees Exposed 265


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; SHE-clonal assay
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-mouse embryo
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-RLV F344 rat embryo
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE; Host-mediated assay
EPA GENETOX PROGRAM 1988, Positive: Mammalian micronucleus; N crassa-forward mutation
EPA GENETOX PROGRAM 1988, Positive: E coli polA with S9; Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae gene conversion
EPA GENETOX PROGRAM 1988, Negative: Cell transform.-BALB/c-3T3; E coli polA without S9
EPA GENETOX PROGRAM 1988, Negative: Sperm morphology-mouse; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Inconclusive: D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Positive: CHO gene mutation
Used as an intermediate in the preparation of other compounds
EPA TSCA Section 8(d) unpublished health/safety studies
On EPA IRIS database
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NIOSH Analytical Method, 1994: Naphthylamines, 5518
NTP 11th Report on Carcinogens,2004:Known to be human carcinogen
OSHA ANALYTICAL METHOD #93


REFERENCES:

CODEN
REFERENCE
85DAAC "Bladder Cancer, A Symposium, Fifth Inter-American Conference on Toxicology and Occupational Medicine, Coral Gables, FL," Lampe, K.F., et al., eds., Coral Gables, FL, Aesculapius Pub., 1966
85JCAE "Prehled Prumyslove Toxikologie; Organicke Latky," Marhold, J., Prague, Czechoslovakia, Avicenum, 1986
ADCSAJ Advances in Chemistry Series. (American Chemical Soc., Distribution Office Dept. 223, POB 57136, West End Stn., Washington, DC 20037) No.1- 1950-
AJPAA4 American Journal of Pathology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1925-
ARGEAR Archiv fuer Geschwulstforschung. (VEB Verlag Volk und Gesundheit Neue Gruenstr. 18, Berlin DDR-1020, Ger. Dem. Rep.) V.1- 1949-
BECCAN Annual Report--Cancer Research Campaign. (Cancer Research Campaign, 2 Carlton House Terrace, London SW1Y 5AR, UK) V.1- 1924-
BECTA6 Bulletin of Environmental Contamination and Toxicology. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1966-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
BLFSBY Basic Life Sciences. (Plenum Pub. Corp., 223 Spring St., New York, NY 10003) V.1- 1973-
CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402)
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG.
EVHPAZ EHP, Environmental Health Perspectives. (U.S. Government Printing Office, Supt of Documents, Washington, DC 20402) No.1- 1972-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
IMSUAI Industrial Medicine and Surgery. (Northbrook, IL) V.18-42, 1949-73. For publisher information, see IOHSA5.
IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979-
ITCSAF In Vitro. (Rockville, MD) V.1-20, 1965-85. For publisher information, see ICDBEO.
JIHTAB Journal of Industrial Hygiene and Toxicology. (Cambridge, MA) V.18-31, 1936-49. For publisher information, see AEHLAU.
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
KHZHAZ Khimiya i Zhizn. Chemistry and Life. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1- 1965-
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823-
MGGEAE Molecular and General Genetics. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.99- 1967-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
NIOSH* National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda.
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information.
NULSAK Nucleus (Calcutta). (Dr. A.K. Sharma, Centre of Advanced Studies in Cell and Chromosome Research, Calcutta, 35 Baliygunge Circular Rd., Calcutta 700 019, India) V.1- 1958-
PMRSDJ Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1981-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
VOONAW Voprosy Onkologii. Problems of Oncology. For English translation, see PONCAU. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1-10, 1928-37; V.1- 1955-
VOONC* Voprosi oncologii (Questions of oncology. Journal of Petrov's Institute of Oncology, B. Zelenina str, 43a, Spb 197110, Russia) V.1- 1955-
XPHBAO U.S. Public Health Service, Public Health Bulletin. (Washington, DC)
ZEKBAI Zeitschrift fuer Krebsforschung. (Berlin, Fed. Rep. Ger.) V.1-75, 1903-71. For publisher information, see JCROD7.

Used as an intermediate in the preparation of other compounds

NIOSH PROFILE (RUBBER MANUFACTURING, SYNTHETIC), SRI, 2/77

NIOSH PROFILE (RUBBER MANUFACTURING, SYNTHETIC), FIRL, 4/78

RTECS Compound Description:
   Tumorigen
   Mutagen

 Click Here for Additional Information about RTECS